European Bioanalysis Forum (EBF)

Drug Development Solutions are attending EBF.

This Open Symposium has become a landmark for bioanalytical discussions in EU and has created a true Forum-like spirit where people meet and open discussions during sessions and presentations contribute to the development of an open mind in bioanalysis. 

Please see our accepted Drug Development Solutions presentations listed below:

Day 2: 25 November 2021

Session 7
Immunogenicity Technology and Applications

11:00 - 11:20 Laura Geary, Scientist
"The importance of characterising critical reagents with a focus on bio-conjugated reagents"

11:40 - 12:00 Issa Jyamubandi, Senior Scientist
"Challenges of developing an ADA assay for Bispecific antibody therapeutic and further ADA characterisation"

Session 8
Biomarker – Technology and Applications

15:00 - 15:20 Coral Munday, Senior Scientist
"Cryoactivation, CRESS, and the Importance of Preanalytics"

Session 9
LBA/CBA – Technical Challenges

14:40 - 15:00 Richard Hughes, Associate Scientific Director
"Pushing the limits of PK analysis: can we meet BMV PK criteria with high sensitivity LBAs"

Session 11
Protein MS – Applications and EBF update

17:20 - 17:40 Richard Lucey, Senior Scientist
"Missed cleavages in bottom-up protein LC-MS workflows: ‘Breaking Bad’-ly cleaved surrogate peptides"

To find out more or to register, please visit EBF